Why the study?
Ginsenoside Rb2 has recently become the focus of studies for its pharmaceutical properties, but its therapeutic effects have not been clinically evaluated.
Ginsenoside Rb2 demonstrates promising preclinical pharmacological effects across multiple disease models, including cardiovascular and metabolic conditions, but lacks clinical evaluation.
This is the authors' abstract. We don't add key points for this paper.
Ginsenoside Rb2 is an active protopanaxadiol-type saponin, widely existing in the stem and leave of ginseng. Rb2 has recently been the focus of studies for pharmaceutical properties. This paper provides an overview of the preclinical and clinical pharmacokinetics for Rb2, which exhibit poor absorption, rapid tissue distribution and slow excretion through urine. Pharmacological studies indicate a beneficial role of Rb2 in the prevention and treatment of diabetes, obesity, tumor, photoaging, virus infection and cardiovascular problems. The underlying mechanism is involved in an inhibition of oxidative stress, ROS generation, inflammation and apoptosis via regulation of various cellular signaling pathways and molecules, including AKT/SHP, MAPK, EGFR/SOX2, TGF-β1/Smad, SIRT1, GPR120/AMPK/HO-1 and NF-κB. This work would provide a new insight into the understanding and application of Rb2. However, its therapeutic effects have not been clinically evaluated. Further studies should be aimed at the clinical treatment of Rb2.
Answers are grounded in this paper and cite their sources.
Ginsenoside Rb2 merits clinical evaluation in cardiometabolic disease; leaves open its efficacy and safety in patients.
No takes yet. Share an insight, caveat, or question.
Miao et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: